Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
2.9
Journals
TropicalMed
Special Issues
Global Burden of Viral Hepatitis
share announcement

Global Burden of Viral Hepatitis

A special issue of Tropical Medicine and Infectious Disease (ISSN 2414-6366). This special issue belongs to the section "Infectious Diseases".

Deadline for manuscript submissions: closed (21 July 2023) | Viewed by 4888

Special Issue Editors

Dr. Faisal Ismail

E-Mail Website
Guest Editor
1. Department of Laboratory, Faculty of Medical Technology, University of Tobruk, Tobruk 1074, Libya
2. Blood Transmitted Diseases Department, National Centre for Disease Control, Tobruk 2654, Libya
3. Infectious Diseases Department, Libyan Medical Research Centre, Kambut, Tobruk 2623, Libya
Interests: viral hepatitis; infectious disease control; epidemiology
Dr. Eman Abdelsameea

E-Mail Website
Guest Editor
Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shibin Al Kawm, Al Minufiyah, Egypt
Interests: viral hepatitis; chronic hepatitis C; hepatocellular carcinoma
Dr. Soghra Haq

E-Mail Website
Guest Editor
Clinical Laboratory Department, Faculty of Medical Technology, University of Tobruk, Tobruk, Libya
Interests: hepatitis c virus; biochemistry, infectious diseases; AMR
Prof. Dr. Mohammad Amjad Kamal

E-Mail Website
Guest Editor
1. Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China
2. King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia
3. Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, Bangladesh
4. Enzymoics, 7 Peterlee Place, Hebersham, NSW 2770, Australia
5. Novel Global Community Educational Foundation, Hebersham, Australia
Interests: biochemistry; neuroscience; enzymology; toxicology; metabolomics; nanomedicines; manual lymph drainage and miRNA; leadership in managing staff performance and chaplaincy
Special Issues, Collections and Topics in MDPI journals
Dr. Islam Mohamad El-Garawani

E-Mail Website
Guest Editor
Faculty of Science, Menoufia University, Shibin Al Kawm, Al Minufiyah, Egypt
Interests: molecular biology; hepatitis; cancer research; infectious diseases

Special Issue Information

Dear Colleagues,

Viral hepatitis infections continue to be a leading cause of morbidity and mortality worldwide, and the elimination of these infections, as a significant public health issue, is a global target. Five distinct viruses—A to E—can cause viral hepatitis with different modes of transmission, variable disease course and severity and different prevalence rates among populations and regions.

Worldwide, hundreds of millions of people have chronic viral hepatitis infections, due to which nearly a million and a half people die each year. Hepatitis B and C can lead to chronic infections and serious liver diseases, and are responsible for the vast majority of viral hepatitis infections and deaths.

The burden caused by viral hepatitis remains high in several populations and is predicted to remain a significant public health problem in the near future. However, up-to-date studies estimating the burden of viral hepatitis from different perspectives, including epidemiology, diagnosis, pathogenesis, natural history, linkage to care, treatment and prevention, are important to assess the current state of viral hepatitis and progress in the prevention and control efforts at national, regional and global levels.

This Special Issue, the “Global Burden of Viral Hepatitis”, aims to assemble a novel collection of valuable resources for the medical and scientific community. Contributions in the form of original research, short communications and reviews are welcome.

Dr. Faisal Ismail
Dr. Eman Abdelsameea
Dr. Soghra Haq
Prof. Dr. Mohammad Amjad Kamal
Dr. Islam Mohamad El-Garawani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Tropical Medicine and Infectious Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • viral hepatitis
  • epidemiology
  • screening
  • incidence
  • treatment
  • linkage to care
  • prevention

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 1713 KiB  
Article
Evaluation of Amino Acids Profile as Non-Invasive Biomarkers of Hepatocellular Carcinoma in Egyptians
by Samar Ebrahim Ghanem, Mohamed Abdel-Samiee, Hala El-Said, Mohamed I. Youssef, Hassan Ahmed ElZohry, Eman Abdelsameea, Inas Moaz, Sayed F. Abdelwahab, Shymaa A. Elaskary, Eman Mohammed Zaher and Marwa Lotfy Helal
Trop. Med. Infect. Dis. 2022, 7(12), 437; https://doi.org/10.3390/tropicalmed7120437 - 13 Dec 2022
Cited by 2 | Viewed by 1512
Abstract
Background: Hepatocellular carcinoma (HCC) is the most dangerous complication of chronic liver disease. It is a multifactorial complicated disease. Hepatitis C and hepatitis B viruses (HCV and HBV, respectively) represent the main causes of HCC in Egypt. Early diagnosis is very important to [...] Read more.
Background: Hepatocellular carcinoma (HCC) is the most dangerous complication of chronic liver disease. It is a multifactorial complicated disease. Hepatitis C and hepatitis B viruses (HCV and HBV, respectively) represent the main causes of HCC in Egypt. Early diagnosis is very important to aid in early intervention. Objectives: The goal of this research is to evaluate the metabolic role of different amino acids as non-invasive biomarkers over the course of HCC. Methods: This study included 302 participants with 97 diagnosed, untreated HCC patients, 81 chronic HCV patients, 56 chronic HBV patients, 18 co-infected patients, and a control group of 50 normal age and gender-matched individuals. All participants provided complete medical histories and underwent complete clinical examinations, abdominal ultrasonography and/or computed tomography, routine laboratory investigations, estimation of serum α-fetoprotein, and determination of amino acid levels using ultra-performance liquid chromatography (UPLC MS/MS). Results: This work revealed a decline in branched chain amino acids (BCAA) and increase in aromatic amino acids (AAA) among infected groups (HCC, HBV, HCV, and co-infected patients) compared to control subjects and a marked change in Fisher’s and the BCAAs/tyrosine molar concentration ratios (BTR) between controls and infected groups. Conclusion: Different amino acids could be used as non-invasive markers to discriminate and follow chronic hepatitis patients to predict the course of HCC. Full article
(This article belongs to the Special Issue Global Burden of Viral Hepatitis)
►▼ Show Figures

Figure 1

Review

Jump to: Research

13 pages, 498 KiB  
Review
Hepatitis C Virus Infection in the Elderly in the Era of Direct-Acting Antivirals: Evidence from Clinical Trials and Real Life
by Nicola Pugliese, Davide Polverini, Ivan Arcari, Stella De Nicola, Francesca Colapietro, Chiara Masetti, Monica Ormas, Roberto Ceriani, Ana Lleo and Alessio Aghemo
Trop. Med. Infect. Dis. 2023, 8(11), 502; https://doi.org/10.3390/tropicalmed8110502 - 18 Nov 2023
Cited by 1 | Viewed by 1692
Abstract
The introduction of direct-acting antiviral agents (DAAs) into clinical practice has revolutionized the therapeutic approach to patients with chronic hepatitis C virus (HCV) infection. According to the most recent guidelines, the first line of treatment for HCV infection involves the use of one [...] Read more.
The introduction of direct-acting antiviral agents (DAAs) into clinical practice has revolutionized the therapeutic approach to patients with chronic hepatitis C virus (HCV) infection. According to the most recent guidelines, the first line of treatment for HCV infection involves the use of one of three pan-genotypic DAA combinations, sofosbuvir/velpatasvir (SOF/VEL), glecaprevir/pibrentasvir (GLE/PIB), and sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX). These drugs have been shown to be effective and safe in numerous clinical trials and real-world studies, but special populations have been neglected. Among the special populations to be treated are elderly patients, whose numbers are increasing in clinical practice. The management of these patients can be challenging, in particular due to multiple comorbidities, polypharmacotherapy, and potential drug–drug interactions. This narrative review aims to summarize the current scientific evidence on the efficacy and safety of DAAs in the elderly population, both in clinical trials and in real-life settings. Although there is still a paucity of real-world data and no clinical trials have yet been conducted in the population aged ≥ 75 years old, some considerations about the efficacy and safety of DAAs in the elderly can be made based on the results of these studies. The pan-genotypic associations of DAAs appear to be as efficacious and safe in the elderly population as in the general population; this is both in terms of similar sustained virologic response (SVR) rates and similar frequencies of adverse events (AEs). However, further studies specifically involving this patient population would be necessary to confirm this evidence. Full article
(This article belongs to the Special Issue Global Burden of Viral Hepatitis)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop